iiinova — where your digital self keeps evolving

Reposted by Christopher Veeck

GfV - Gesellschaft für Virologie @gesvirologie.bsky.social · 26/08/2026

Einblick in das BSL4-Labor in Marburg: Der Beitrag zeigt, wie Forschung mit hochpathogenen Viren unter strengsten Sicherheitsbedingungen abläuft und warum diese Arbeit wichtig ist, um die Viren besser zu verstehen und Impfstoffe und antivirale Therapien zu entwickeln (CR) www.joyn.de/serien/galil...

joyn.de

Galileo Staffel 2026 Folge 162: Im Kampf gegen Viren: Inside Hochsicherheitslabor

Der Ebola-Ausbruch im Kongo hält die Welt in Atem. Experten sprechen vom bisher tödlichsten und schnellsten Ausbruch in der Geschichte. Doch was hinter…

083

Christopher Veeck @cveeck.bsky.social · 30/09/2025

I’m reminded how important it is to stay open-minded: proximity-induced modalities are still new to me in antivirals, but already well established in oncology – which made the discussions especially rewarding. #DPhG2025

010

Christopher Veeck @cveeck.bsky.social · 30/09/2025

As a molecular virologist, it’s humbling and inspiring to exchange ideas with experts in medicinal chemistry and drug development at the interface of chemistry and virology. #DPhG2025

110

Christopher Veeck @cveeck.bsky.social · 30/09/2025

Today I had the chance to speak at the Annual Meeting of the German Pharmaceutical Society in Freiburg about targeted protein degradation as a novel paradigm in antiviral therapy. #DPhG2025

110

Christopher Veeck @cveeck.bsky.social · 08/05/2025

This work proves that targeted protein degradation can go beyond enzymatic targets—opening up new viral proteins and ligands for therapeutic intervention. A promising step forward for antiviral PROTACs.

000

Christopher Veeck @cveeck.bsky.social · 08/05/2025

We show that inactive ligands, binding outside of catalytic pockets, can still serve as potent warheads—expanding the antiviral degrader design space to new viral targets.

100

Christopher Veeck @cveeck.bsky.social · 08/05/2025

Our lead compound, LLP019, robustly degraded Mpro in a cereblon-dependent manner and significantly reduced viral titers—despite its warhead being inactive as an inhibitor. Consequently, degradation, not inhibition, drove the antiviral effect.

100

Christopher Veeck @cveeck.bsky.social · 08/05/2025

We redesigned pelitinib, an allosteric binder of SARS-CoV-2 Mpro, to create a series of degraders—leveraging its binding mode to go beyond conventional targeting of catalytic clefts.

100

Christopher Veeck @cveeck.bsky.social · 08/05/2025

We asked: can ligands that bind outside—or in absence of—a catalytic cleft act as warheads for antiviral PROTACs? Until now, most such degraders targeted active sites. We set out to challenge that paradigm.

100

Reposted by Christopher Veeck

GfV - Gesellschaft für Virologie @gesvirologie.bsky.social · 21/02/2025

In Deutschlands Hochsicherheitslaboren wird an hochpathogenen Viren wie dem Ebola Virus geforscht. In Marburg entsteht aktuell ein neuer Laborbau. Einen aktuellen Einblick in das Projekt geben @markuseickmann.bsky.social und @crnlsrhd.bsky.social: pandemienetzwerk-hessen.de/neues-hochsi... (CR)

pandemienetzwerk-hessen.de

Neues Hochsicherheitslabor: Mehr Forschung zur Vorbereitung auf Risiko-Viren - Pandemie Netzwerk Hessen

An der Virologie der Universität Marburg entsteht ein neues Hochsicherheitslabor, ein BSL-4-Labor, um sich besser auf Pandemien vorzubereiten

0173

Christopher Veeck @cveeck.bsky.social · 31/01/2025

While this marks the end of an important chapter in my life, I see it as the beginning of a new journey—one that I hope will lead me to exciting destinations, surrounded by inspiring mentors, colleagues, and friends in academia. #PhDone #OneDegreeHotter

020

Christopher Veeck @cveeck.bsky.social · 31/01/2025

A heartfelt thank you to everyone who has supported me throughout this journey. I am especially grateful to Prof. Becker, whose guidance made all of this possible in the first place, and to Dr. Anke Werner, who has been not only an incredible mentor but also a dear friend.

150

Christopher Veeck @cveeck.bsky.social · 31/01/2025

Yesterday was a truly special day – I successfully defended my doctoral thesis at the Institute of Virology in Marburg! After years of education, hard work, research, and perseverance—combined with passion, joy, and, at times, tears and challenges—I am beyond grateful to have reached this milestone.

170